BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 20126582)

  • 1. Expression of AKR1C3 in renal cell carcinoma, papillary urothelial carcinoma, and Wilms' tumor.
    Azzarello JT; Lin HK; Gherezghiher A; Zakharov V; Yu Z; Kropp BP; Culkin DJ; Penning TM; Fung KM
    Int J Clin Exp Pathol; 2009 Nov; 3(2):147-55. PubMed ID: 20126582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential expression of type 2 3α/type 5 17β-hydroxysteroid dehydrogenase (AKR1C3) in tumors of the central nervous system.
    Park AL; Lin HK; Yang Q; Sing CW; Fan M; Mapstone TB; Gross NL; Gumerlock MK; Martin MD; Rabb CH; Fung KM
    Int J Clin Exp Pathol; 2010 Mar; 3(8):743-54. PubMed ID: 21151387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancer.
    Byrns MC; Duan L; Lee SH; Blair IA; Penning TM
    J Steroid Biochem Mol Biol; 2010 Feb; 118(3):177-87. PubMed ID: 20036328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma.
    Fung KM; Samara EN; Wong C; Metwalli A; Krlin R; Bane B; Liu CZ; Yang JT; Pitha JV; Culkin DJ; Kropp BP; Penning TM; Lin HK
    Endocr Relat Cancer; 2006 Mar; 13(1):169-80. PubMed ID: 16601286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppressed expression of type 2 3alpha/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) in endometrial hyperplasia and carcinoma.
    Zakharov V; Lin HK; Azzarello J; McMeekin S; Moore KN; Penning TM; Fung KM
    Int J Clin Exp Pathol; 2010 Jul; 3(6):608-17. PubMed ID: 20661409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aldo-keto reductase family 1 member C3 (AKR1C3) is expressed in adenocarcinoma and squamous cell carcinoma but not small cell carcinoma.
    Miller VL; Lin HK; Murugan P; Fan M; Penning TM; Brame LS; Yang Q; Fung KM
    Int J Clin Exp Pathol; 2012; 5(4):278-89. PubMed ID: 22670171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developmental evaluation of aldo-keto reductase 1C3 expression in the cryptorchid testis.
    Ashley RA; Yu Z; Fung KM; Frimberger D; Kropp BP; Penning TM; Lin HK
    Urology; 2010 Jul; 76(1):67-72. PubMed ID: 19942269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aldo-keto reductase 1C3 is overexpressed in skin squamous cell carcinoma (SCC) and affects SCC growth via prostaglandin metabolism.
    Mantel A; Carpenter-Mendini A; VanBuskirk J; Pentland AP
    Exp Dermatol; 2014 Aug; 23(8):573-8. PubMed ID: 24917395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells.
    Jamieson SM; Gu Y; Manesh DM; El-Hoss J; Jing D; Mackenzie KL; Guise CP; Foehrenbacher A; Pullen SM; Benito J; Smaill JB; Patterson AV; Mulaw MA; Konopleva M; Bohlander SK; Lock RB; Wilson WR
    Biochem Pharmacol; 2014 Mar; 88(1):36-45. PubMed ID: 24434189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5α-reductase inhibitor finasteride.
    Byrns MC; Mindnich R; Duan L; Penning TM
    J Steroid Biochem Mol Biol; 2012 May; 130(1-2):7-15. PubMed ID: 22265960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of aldo-keto reductase family 1 member C3 (AKR1C3) in neuroendocrine tumors & adenocarcinomas of pancreas, gastrointestinal tract, and lung.
    Chang TS; Lin HK; Rogers KA; Brame LS; Yeh MM; Yang Q; Fung KM
    Int J Clin Exp Pathol; 2013; 6(11):2419-29. PubMed ID: 24228104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aldo-keto reductases AKR1C1, AKR1C2 and AKR1C3 may enhance progesterone metabolism in ovarian endometriosis.
    Hevir N; Vouk K; Sinkovec J; Ribič-Pucelj M; Rižner TL
    Chem Biol Interact; 2011 May; 191(1-3):217-26. PubMed ID: 21232532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aldo-keto reductase 1C3 is expressed in differentiated human epidermis, affects keratinocyte differentiation, and is upregulated in atopic dermatitis.
    Mantel A; Carpenter-Mendini AB; Vanbuskirk JB; De Benedetto A; Beck LA; Pentland AP
    J Invest Dermatol; 2012 Apr; 132(4):1103-10. PubMed ID: 22170488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3.
    Hofman J; Malcekova B; Skarka A; Novotna E; Wsol V
    Toxicol Appl Pharmacol; 2014 Aug; 278(3):238-48. PubMed ID: 24832494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue distribution of human AKR1C3 and rat homolog in the adult genitourinary system.
    Azzarello J; Fung KM; Lin HK
    J Histochem Cytochem; 2008 Sep; 56(9):853-61. PubMed ID: 18574251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aldo-keto reductase 1C3 may be a new radioresistance marker in non-small-cell lung cancer.
    Xie L; Yu J; Guo W; Wei L; Liu Y; Wang X; Song X
    Cancer Gene Ther; 2013 Apr; 20(4):260-6. PubMed ID: 23519145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs.
    Byrns MC; Penning TM
    Chem Biol Interact; 2009 Mar; 178(1-3):221-7. PubMed ID: 19010312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships.
    Adeniji AO; Twenter BM; Byrns MC; Jin Y; Chen M; Winkler JD; Penning TM
    J Med Chem; 2012 Mar; 55(5):2311-23. PubMed ID: 22263837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3.
    Guise CP; Abbattista MR; Singleton RS; Holford SD; Connolly J; Dachs GU; Fox SB; Pollock R; Harvey J; Guilford P; Doñate F; Wilson WR; Patterson AV
    Cancer Res; 2010 Feb; 70(4):1573-84. PubMed ID: 20145130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical implications of aldo-keto reductase family 1 member C3 and its relationship with lipocalin 2 in cancer of the uterine cervix.
    Wu CH; Ko JL; Chen SC; Lin YW; Han CP; Yang TY; Chien MH; Wang PH
    Gynecol Oncol; 2014 Feb; 132(2):474-82. PubMed ID: 24316309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.